New South Wales announce RSV (respiratorysyncytialvirus) immunisation program

Beyfortus^™ (nirsevimab) – NSW Health RSV (Respiratory Syncytial Virus) vulnerable babies program

NSW Health RSV (respiratory syncytial virus) vulnerable babies program will be implemented in a phased approach that prioritises the most vulnerable babies and infants.

Infants who are vulnerable to severe illness from RSV are eligible for a free monoclonal antibody Beyfortus^™ (nirsevimab) immunisation. RSV monoclonal antibodies are a passive immunisation that provides antibodies directly to the infant so they have immediate protection against RSV. The trade name of nirsevimab is Beyfortus^™.

Beyfortus^™ (nirsevimab) will be initially offered to hospitalised infants in 2024 who meet the following eligibility criteria:

• babies born before 37 weeks gestation and after 31 October 2023
• Aboriginal and Torres Strait Islander babies born after 31 October 2023
• other infants living with specific chronic and complex health conditions.

https://www.health.nsw.gov.au/immunisation/Pages/respiratory-syncytial-virus.aspx